Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study

Wen-Xia HuDepartment of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050012, People’s Republic of China

Jing-Cui PengDepartment of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050012, People’s Republic of China

Yun WangDepartment of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050012, People’s Republic of China

Hao JinDepartment of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050012, People’s Republic of China

Nan GengDepartment of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050012, People’s Republic of ChinaCorrespondence[email protected]

https://orcid.org/0000-0001-8953-1438

Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study

Articles from other publishers (1)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study

Citations (1)

Articles from other publishers (1)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date